Aridis Pharmaceuticals Announces $2 Million Offering
- Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock (or pre-funded warrant) and accompanying warrant. Each warrant will have an exercise price per share of $0.20, will be exercisable immediately and will terminate on the five year anniversary of the date of issuance. The closing of the offering is expected to occur on or about August 4, 2023, subject to the satisfaction of customary closing conditions.
- 08/02/2023
|
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
- LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients.
- 07/17/2023
|
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
- Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
- 07/13/2023
|
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
- LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation under the Generating Antibiotic Incentives Now (GAIN) Act for AR-301, a fully human IgG1 monoclonal antibody (mAb) currently in Phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive Staphylococcus aureus in critically ill hospitalized patients.
- 07/12/2023
|
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
- Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
- 06/21/2023
|
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
- Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
- 06/01/2023
|
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
- Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
- 06/01/2023
|
5 Hot Penny Stocks To Watch With Big News This Week
- Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
- 05/31/2023
|
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
- Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
- 03/14/2023
|
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
- Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/21/2022
|
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
- Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/16/2022
|
Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing
- Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
- 07/01/2022
|
Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates
- Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/16/2022
|
Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop
- As far as short squeeze stocks go, these five companies top the list in terms of both short interest and borrow fee rates right now. The post Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace.
- 02/14/2022
|
5 Short Squeeze Candidate To Watch: Aridis Pharmaceuticals Tops List, EVgo, Indonesia Energy Corp And More
- Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
- 02/14/2022
|
4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
- Are these short squeeze penny stocks on our watch list right now? The post 4 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/11/2022
|
Aridis Pharmaceuticals Stock (ARDS): Why The Price Surged Up Today
- The stock price of Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) increased by over 30% during intraday trading today. This is why it happened.
- 01/27/2022
|
4 Penny Stocks Up Big With The Stock Market Down Today; Time To Buy?
- Thanks to continued fear and uncertainty, the stock market is down again… The post 4 Penny Stocks Up Big With The Stock Market Down Today; Time To Buy? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/24/2022
|
Can These Penny Stocks Climb This Week? 4 To Watch Right Now
- Are these penny stocks on your watchlist for next week? The post Can These Penny Stocks Climb This Week?
- 01/23/2022
|
3 Penny Stocks That Exploded in Premarket Trading Today
- These penny stocks climbed during premarket trading today, here's why The post 3 Penny Stocks That Exploded in Premarket Trading Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/30/2021
|
Are These Top Penny Stocks Worth Buying Right Now?
- If you're making a penny stocks watchlist right now, check these three out The post Are These Top Penny Stocks Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/22/2021
|
Best Penny Stocks to Buy as 2021 Ends? 3 to Watch Right Now
- Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?
- 12/21/2021
|
Aridis Stock Rallies After Positive Preclinical Data For COVID-19 Antibody Against Omicron
- Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody (mAb) cocktail AR-701. The data show that the antibody is broadly reactive against the omicron and other COVID-19 variants, SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome Coronavirus), and seasonal ('common cold') human coronaviruses.
- 12/21/2021
|
Aridis Pharmaceuticals Stock (ARDS): Why The Price Surged Today
- The stock price of Aridis Pharmaceuticals Inc (NASDAQ: ARDS) increased by over 105% pre-market today. This is why it happened.
- 12/21/2021
|
New Strong Sell Stocks for November 15th
- ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.
- 11/15/2021
|
Analysts Estimate ARIDIS PHARMACT (ARDS) to Report a Decline in Earnings: What to Look Out for
- ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2021
|
Aridis Pharmaceuticals Announces $25 Million Registered Direct Offering Priced at a Premium to Market
- LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,947,556 shares of the Company's common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 2,473,778 shares of the Company's common stock, at an effective purchase price of $5.053 per share of common stock (or common stock equivalent) and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules.
- 08/02/2021
|
Aridis Pharmaceuticals' COVID mAb Ranks Among the Top 5 Most Potent COVID-19 mAbs Evaluated by the Coronavirus Immunotherapeutics Consortium (CoVIC)
- LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that animal efficacy data reported by the Coronavirus Immunotherapeutics Consortium (CoVIC) showed that the Company's COVID-19 monoclonal antibody (mAb) AR-711, one of two mAbs in the AR-712 cocktail, ranks among the top 5 most potent mAbs that the CoVIC consortium have studied to date.
- 07/26/2021
|
Aridis Pharma's COVID-19 Antibody Neutralizes Delta Variant In Animal Model
- Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL). Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC's variants of interest and concern lists.
- 07/13/2021
|
Aridis Pharmaceuticals COVID mAb AR-712 Neutralizes SARS-CoV-2 Delta Variant
- LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant virus SARS-CoV-2 at a highly effective level (~20ng/mL).
- 07/12/2021
|
Strength Seen in ARIDIS PHARMACT (ARDS): Can Its 10% Jump Turn into More Strength?
- ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/09/2021
|
Aridis Pharmaceuticals Announces First Quarter 2021 Results
- LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the first quarter ended March 31, 2021.
- 05/11/2021
|
CORRECTING and REPLACING Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)
- PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
- 04/27/2021
|
Kermode Biotechnologies Announced that it is Actively Engaged in Discovery to Identify the Mode of Transmission for the African Swine Fever Virus (ASFV)
- PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
- 04/27/2021
|
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
- LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the fourth quarter ended December 31, 2020.
- 03/30/2021
|
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
- LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced an interview with Vu Truong, Ph.D.
- 03/26/2021
|
Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants
- Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company says that the cocktail referred to as AR-712 will provide broad coverage of all known high-risk strains.
- 02/23/2021
|
Aridis Pharmaceuticals Provides Multiple Program Updates Including the Addition of a Second Inhaled Antibody to Neutralize Newly Emerging COVID-19 Mutated Variants
- LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today that it has augmented its inhaled...
- 02/23/2021
|
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
- SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the...
- 11/20/2020
|
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
- SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the Company will present at the ROTH...
- 10/27/2020
|
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
- Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
- 09/11/2020
|
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for the second quarter ended June 30, 2020.
- 08/11/2020
|
Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to “Hold”
- Zacks Investment Research upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The […]
- 07/19/2020
|
We Think Aridis Pharmaceuticals (NASDAQ:ARDS) Can Easily Afford To Drive Business Growth
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 07/15/2020
|
H.C. Wainwright Thinks Neovasc's Stock is Going to Recover - Markets
- H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Neovasc (NVCN – Research Report) today and set a price
- 07/02/2020
|
Is the Vanguard Property ETF a good long-term investment?
- Is the Vanguard Australian Property Securities ETF (ASX: VAP) a good long-term investment for ASX dividend income in 2020?
- 07/02/2020
|
Cel-Sci (CVM) Receives a Buy from H.C. Wainwright - Markets
- In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cel-Sci (CVM – Research Report),
- 06/29/2020
|
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN), Novavax (NASDAQ: NVAX) and Arena Pharma (NASDAQ: ARNA) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Novan (NOVN
- 06/29/2020
|
Aridis Pharmaceuticals to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced that Vu Truong, Ph.D., Chief Executive Officer, will participate in Cantor Fitzgerald's Virtual Symposium: "Winning Ways to Treat Infections and COVID-19" being held on Tuesday, June 30, 2020.
- 06/26/2020
|
Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from Northland Securities - Markets
- In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Aridis Pharmaceuticals (ARDS – Research
- 06/22/2020
|
Nabriva (NBRV) Gets a Buy Rating from Northland Securities - Markets
- Northland Securities analyst Carl Byrnes maintained a Buy rating on Nabriva (NBRV – Research Report) today and set a price
- 06/22/2020
|
Analysts Offer Insights on Healthcare Companies: Heron Therapeutics (NASDAQ: HRTX) and Tandem Diabetes Care (NASDAQ: TNDM) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Heron Therapeutics
- 06/22/2020
|
Aridis Reports AR-501 Clinical Data: Positive Safety Data in Healthy Subjects of a Phase 1/2a Clinical Trial
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced today positive results from the Phase 1 portion of its Phase 1/2a clinical trial of AR-501, an inhaled formulation of gallium citrate being developed for the treatment of chronic lung infections in patients with cystic fibrosis (CF). The Phase 1/2a clinical trial, which is being funded by the Cystic Fibrosis Foundation, is a randomized, double blinded, placebo-controlled study evaluating the safety and pharmacokinetics in healthy volunteers and Pseudomonas aeruginosa infected CF patients. AR-501 is being developed as a once-per-week dosing regimen that is self-administered using a hand-held nebulizer device.
- 06/22/2020
|
The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions
- Biotech stocks rebounded along with the broader market in the week ended June 19. The week was a busy one from the perspective of PDUFA dates, with the FDA issuing approvals...
- 06/21/2020
|
Xconomy: Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
- The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on
- 06/19/2020
|
Aridis Pharmaceuticals to Discuss APEX™ in Virtual Fireside Chat Hosted by Cantor Fitzgerald on June 25th
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will participate in a Cantor Fitzgerald hosted Virtual Fireside Chat on Thursday, June 25, 2020 at 11:00 AM ET.
- 06/18/2020
|
Bose gives up on its augmented reality sound project
- A tough year for Bose
- 06/16/2020
|
Northland Securities Reaffirms Their Buy Rating on vTv Therapeutics (VTVT) - Markets
- In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on vTv Therapeutics (VTVT – Research
- 06/15/2020
|
Aridis Pharmaceuticals Appoints Dr. Hasan Jafri as Chief Medical Officer
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has appointed Dr. Hasan Jafri as Chief Medical Officer (CMO). Dr. Jafri replaces Dr. Paul Mendelman who has been serving as the Company's interim CMO since October, 2019 and will transition to the role of senior medical advisor to the Company.
- 06/15/2020
|
Healthcare Administrative Partners & Strategic Radiology–PSO Collaborate on Incidental Findings Communication
- Healthcare Administrative Partners (HAP), a comprehensive radiology revenue cycle management solutions provider, today announces their partnership wit
- 05/14/2020
|
Aridis Pharmaceuticals Announces First Quarter 2020 Results
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2020.
- 05/12/2020
|
Bakkafrost's (BKFKF) CEO Regin Jacobsen on Q1 2020 Results - Earnings Call Transcript
- Bakkafrost PF (OTCPK:BKFKF) Q1 2020 Earnings Conference Call May 05, 2020 02:00 AM ET Company Participants Regin Jacobsen – Chief Executive Officer Høgni Jakobs
- 05/10/2020
|
Will Aridis Pharmaceuticals Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals
- 05/07/2020
|
Aridis Pharmaceuticals Enrolls Its First COVID-19 Patient in Ongoing Phase 3 AR-301 Clinical Trial in Ventilator Associated Pneumonia (VAP)
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the enrollment of its first COVID-19 patient in the Company's ongoing Phase 3 clinical trial of AR-301, a monoclonal antibody against S. aureus induced pneumonia in patients who were already on mechanical ventilators.
- 05/04/2020
|
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 05/02/2020
|
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today its participation in Maxim Group's Infectious Disease Virtual Conference being held on May 5, 2020. Vu Truong, Ph.D., Chief Executive Officer, will be a speaker on two panels entitled "Non-antibiotic Anti-infectives" and "COVID-19 (Therapeutics)."
- 04/29/2020
|
Aridis Pharmaceuticals (NASDAQ:ARDS) and Amarin (NASDAQ:AMRN) Financial Comparison
- Aridis Pharmaceuticals (NASDAQ:ARDS) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Volatility and Risk Aridis Pharmaceuticals has a beta of -0.3, suggesting that its share price is 130% […]
- 04/17/2020
|
Can Aridis Pharmaceuticals’ APEX Platform Be Used to Target Coronavirus? Analyst Weighs In
- If nothing else, the COVID-19 pandemic has spurred vast cooperation in the healthcare space. Having said that, it remains unclear as to what approach will be the most effective in stopping the deadly virus from continuing its romp around the world.Antiviral treatments such as remdesivir have garnered
- 04/15/2020
|
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
- The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
- 04/15/2020
|
Aridis Pharmaceuticals (NASDAQ:ARDS) Research Coverage Started at Maxim Group
- Stock analysts at Maxim Group began coverage on shares of Aridis Pharmaceuticals (NASDAQ:ARDS) in a research report issued to clients and investors on Friday, TipRanks reports. The brokerage set a “buy” rating and a $17.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 172.00% from the stock’s current price. […]
- 04/11/2020
|
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS) today and set a price target of $17.00. The company's shares
- 04/10/2020
|
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
- Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS – Research Report) today and set a
- 04/10/2020
|
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
- Northland Securities analyst Carl Byrnes maintained a Buy rating on Aridis Pharmaceuticals (ARDS) today and set a price target of $22.00. The company's
- 04/09/2020
|
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
- Northland Securities analyst
Carl Byrnes
maintained a
Buy
rating on Aridis Pharmaceuticals (
ARDS
–
Research Report
) today and set a price target of
$22.00
. The company’s shares closed last Wednesday at $5.79.
According to
TipRanks.com
, Byrnes is
- 04/09/2020
|
Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today reported financial and corporate results for the fourth quarter ended December 31, 2019.
- 04/08/2020
|
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
- RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation. have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of RLF-100 (Aviptadil) in the treatment of Acute and Moderate Respiratory Distress in patients infected
- 03/26/2020
|
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
- RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation, have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of RLF-100 (Aviptadil) in the treatment of Acute and Moderate Respiratory Distress in patients infected
- 03/26/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
Stocks To Watch: Fading The Fear
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 03/07/2020
|
Aridis Pharmaceuticals to Postpone Investor Day Due to Coronavirus Concerns
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today the postponement of its Investor Day scheduled for Thursday, March 12th, 2020 to a future date due to concerns related to the coronavirus (COVID-19).
- 03/06/2020
|
Aridis Pharmaceuticals to Present at the 32nd Annual ROTH Conference
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that Vu Truong, Ph.D., Chief Executive Officer, will present at the 32nd Annual ROTH Conference on Monday, March 16, 2020 at 4:00 pm PDT. The conference will be held at The Ritz Carlton, Laguna Niguel in Orange County, CA.
- 03/05/2020
|
Aridis Pharmaceuticals Provides Update on Investor Day Featuring Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, is pleased to provide an update on its Investor Day being held on Thursday, March 12th, 2020 in New York City from 12:00PM-2:00PM EDT.
- 03/04/2020
|
San Jose biotech incubator where Impossible Foods hatched expands at new site
- In addition to Impossible Foods, the incubator was an early home to three companies that were acquired by Swiss pharma giant Roche Holdings — Ariosa Diagnostics, Genia Technologies and Geneweave. Another BioCube alumnus, Aridis Pharmaceuticals, went public in 2018.
- 02/28/2020
|
Stifel likes Alector and Denali in premarket analyst action
- Alector (NASDAQ:ALEC) initiated with Buy rating and $44 (52% upside) price target at Stifel.Aridis Pharmaceuticals (NASDAQ:ARDS) initiated with Buy rating and $18 (193% upside) price target at Roth Ca
- 02/19/2020
|
Aridis Pharmaceuticals to Host Investor Day Showcasing APEX™ Technology Platform and Key Opinion Leader Panels on Cystic Fibrosis and Pneumonia
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it will host an Investor Day on Thursday, March 12th, 2020 in New York City from 12:00PM-2:00PM EST.
- 02/18/2020
|
Aridis Pharmaceuticals Presents APEX™ Antibody Discovery and Production Platform Technology at the 19th Annual CHI PepTalk Conference
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company") presented a comprehensive profile of its APEX™ platform technology at the antibody and cell engineering conference 19th Annual PepTalk: The Protein Science Week on Friday, January 24, 2020 in San Diego, CA USA.
- 01/28/2020
|
We're Hopeful That Aridis Pharmaceuticals (NASDAQ:ARDS) Will Use Its Cash Wisely
- Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- 01/17/2020
|
3 Beaten-Up Biotech Stocks That Just Got More Enticing
- The Biotech sector came back to life towards the end of 2019. The Nasdaq Biotechnology Index jumped up 20% between October and December, beating the S&P; 500’s 9% increase. The surge, according to some analysts, is set to continue into 2020.Washington’s lack of attention to drug pricing or Medicare for All, due to present focus on trade talks and the impeachment process, along with the J.P. Morgan Healthcare Conference between Jan. 13-16, which usually generates investor interest, are both seen as reasons to be bullish. Furthermore, according to Jared Holz, a sector strategist at Jefferies, the beginning of the year is a likely period for mergers and acquisitions.“We continue to think there is much more consolidation on the horizon given the pipeline needs across large cap bio-pharma,” said Holz.This leads us to think now is a good time for bargain hunting in the Healthcare sector. So, we dug into TipRanks’ Stock Screener to find three biotech stocks that have yet to catch up with the uptick in the sector’s fortunes, but which according to the analysts, are ready to make some upward movement in 2020. Let check out the data.bluebird bio (BLUE)No one is doubting the fact that gene therapy company bluebird bio has had a rough going. We’re talking about a 50% fall in the past two years. However, Oppenheimer analyst Mark Breidenbach believes that the drop presents investors with a buying opportunity.bluebird recently presented at the annual American Society of Hematology (ASH) conference and Breidenbach was there to get the lowdown. The 4-star analyst is forecasting "blue skies” following Bluebird’s presentation.bluebird has one product approved for patients in the EU; Zynteglo, the first gene therapy approved for transfusion-dependent β-thalassemia (TDT). Breidenbach expects “Zynteglo sales in Europe to slowly begin ramping in 2020.” Bluebird plans to initiate a rolling BLA (Biological License Application) for the treatment in the US by the end of the year.Furthermore, the company has several drugs in the pipeline, of which data presented from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for sickle cell disease (SCD), was a highlight for the analyst.“At ASH, bluebird showcased tangible signs of progress across its hemoglobinopathy pipeline, with especially impressive results in sickle cell anemia (SCA) [...] Nine treated patients with ≥6 months follow-up showed sustained hematological improvements and a 99% reduction in serious symptoms including VOC and ACS episodes,” said Breidenbach.A further catalyst for Breidenbach is bluebird’s partnership with Bristol-Myers Squibb. The two are collaborating on a therapy candidate for patients with relapsed and refractory multiple myeloma, and positive top-line results from KarMMa, a Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121) met its primary endpoint and key secondary endpoint.Breidenbach noted, “We expect pivotal data from KarMMa to support FDA approval of ide-cel by late 2020, and we believe new data from competing products could help calibrate expectations for its commercial potential."As a result, Breidenbach upgraded his rating on BLUE from Perform to Outperform, alongside a price target of $135, implying upside potential of over 50%. (To watch Breidenbach’s track record, click here)On the Street, bluebird currently has 8 Buys and 5 Hold ratings, which coalesce into a Moderate Buy consensus rating. The average price target comes in at $118.67, and represents possible upside of 36%. (See BLUE stock analysis on TipRanks)Aridis Pharmaceuticals (ARDS)Another company which struggled in 2019, is fellow micro-cap Aridis Pharmaceuticals. The biotech saw out the year with its share price down by 60%.However, H.C. Wainwright analyst Vernon Bernardino believes now is the right time for investors to hop onboard. The analyst initiated coverage on Aridis shares with a Buy rating, and set a price target of $7, implying upside potential of 57%. (To watch Bernardino’s track record, click here).So, what has piqued the analyst’s interest, then? Bernardino believes Aridis has “product candidates that present novel targets and mechanisms of action” and a clinical strategy which “is designed to achieve superiority and maximize the probability of adoption of Aridis’ fully human mAbs as first-line anti-bacterial therapies.” The analyst added, "We expect Aridis’ mAb anti-bacterial candidates to differentiate themselves through their potential to be active against antibiotic resistant strains of urgent threat bacteria.”Aridis has several therapies in the pipeline. Its most advanced candidate is AR-301, currently in a Phase 3 trial for hospital-acquired pneumonia (HAP) infection and ventilator-associated pneumonia (VAP) infection bought on by the Gram-positive bacteria, Staphylococcus aureus (S. aureus). Bernardino thinks the drug has potential for regulatory approval by 2022 and projects AR-301 could reach annual sales of approximately $700 million by 2030.Bernardino further expounded, “We believe the potential for results from the ongoing Phase 3 trial with AR-301 as adjunct therapy in patients with hospital acquired and ventilator-associated pneumonia to be a positive catalyst in early 2020 is under-appreciated.”Similarly, other Wall Street analysts like what they’re seeing. With 3 Buy ratings received in the last three months, the stock earns a ‘Strong Buy’ Street consensus. At an $18 average price target, analysts see 270% upside potential in store for Aridis. (See Aridis price targets and analyst ratings on TipRanks)Ocugen Inc (OCGN)It’s been a miserable 2019 for investors in clinical-stage biopharmaceutical company Ocugen, which saw its stock price cut nearly 90%. The low value, though, could also present opportunity, at least according to H.C. Wainwright analyst Swayampakula Ramakanth.Ramakanth initiated coverage on Ocugen with a Buy rating and set a price target of $1.25. Should the target be met, investors will see a solid 140% gains over the next 12 months. (To watch Ramakanth’s track record, click here)Ocugen’s lead candidate is OCU300, a treatment for ocular graftversus-host disease (oGVHD), a condition which can cause damage to the ocular surface and tear-producing glands and has no approved therapy. The drug is currently in a Phase 3 trial and topline results are expected in 2H20. According to estimates, there are 63,000 oGVHD patients in the US, a figure expected to grow to 140,000 by 2030.Ramakanth noted, “Given the promising data generated so far, we believe that OCU300 Phase 3 study is likely to report a positive readout, which could be a major catalyst. Additionally, OCU300 is the first and only product candidate that has received Orphan Drug Designation (ODD) from the FDA for oGVHD. We currently project OCU300 risk-adjusted revenues to reach $141M by 2030, growing from $5M in 2021.”There is little action on the Street heading Ocugen’s way right now, with only one other analyst chiming in with a view on the micro-cap’s prospects. An additional Buy rating means Ocugen qualifies as a Moderate Buy. The average price target, though, is $1.63, and implies massive upside potential of 213%. (See Ocugen price targets and analyst ratings on TipRanks)
- 01/03/2020
|
The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) Aptose Biosciences Inc (NASDAQ: APTO ) ...
- 01/02/2020
|
Aridis Pharmaceuticals Appoints Michael A. Nazak as Chief Financial Officer
- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today announced the appointment of Michael A. Nazak as its Chief Financial Officer (CFO) effective January 1, 2020. Mr. Nazak, who joined Aridis in November 2018, has been serving as Vice President, Finance and replaces Fred Kurland who has chosen to retire but will continue to support the Company as a consultant.
- 01/02/2020
|
Aridis Pharmaceuticals Announces Third Quarter 2019 Results
- SAN JOSE, Calif. , Nov. 13, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully ...
- 11/13/2019
|
Introducing Aridis Pharmaceuticals (NASDAQ:ARDS), The Stock That Slid 52% In The Last Year
- The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Aridis...
- 10/19/2019
|
Aridis Pharmaceuticals Appoints Infectious Disease Expert Paul Mendelman, MD as Interim Chief Medical Officer
- SAN JOSE, Calif. , Oct. 11, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to ...
- 10/11/2019
|
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
- SAN JOSE, Calif., Sept. 30, 2019 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, announced today that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV (SIBV) and the Serum Institute of India, Ltd. The agreement grants Serum AMR a license to multiple programs from Aridis for certain limited territories and access the Company's MabIgX® platform technology for asset identification and selection. As part of the agreement, Aridis will receive the remaining upfront cash payment of $10 million, which is in addition to the $5 million that was initially received when the companies signed an option agreement on July 30, 2019.
- 09/30/2019
|
Augmented reality: a vision for the future of manufacturing
- Augmented reality's potential to transform manufacturing is undeniable - but how close are we to AR being widely adopted?
- 08/21/2018
|
